ArticleFrontiers in endocrinology2026
Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated thyroid carcinoma (DTC) is a common endocrine malignancy, and cervical lymph node metastasis (LNM) represents the predominant pattern of disease recurrence. For patients who develop persistent or recurrent cervical lesions following total thyroidectomy and radioactive iodine (131I) therapy, conventional reoperation or additional 131I therapy often provides limited efficacy and may carry increased procedural risks. Methods: This single-center retrospective cohort study included 238 patients with persistent or recurrent cervical LNM after prior thyroidectomy and 131I therapy who were treated between January 2020 and January 2024. Among them, 118 patients received 125I seed implantation with thyroid-stimulating hormone (TSH) suppression. After 1:1 propensity score matching (PSM), 110 patients were included in each group for analysis. Short-term efficacy, thyroglobulin (Tg), radiologic changes, dosimetric consistency, survival outcomes, and adverse events were compared. Dynamic changes in Tg levels and the short-axis diameter of LNM were analyzed using a linear mixed-effects model. Results: After PSM, the partial response rates at 6 and 12 months were significantly higher in the 125I+TSH group. 125I+TSH therapy was an independent predictor of partial response. Patients in the 125I+TSH group exhibited a faster decline in Tg levels, with an average reduction of approximately 14.5% per month and a reduction in the short-axis diameter of LNM of 4.8% per month, corresponding to biochemical and morphological half-lives of 4.4 and 14.2 months, respectively. The overall incidence of adverse events was low. Conclusions: 125I seed implantation combined with TSH suppression therapy accelerates Tg decline and lesion regression and demonstrates good safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.